Patients with SLE presented increased levels of circulating Galectin-3 [21.5(6.1) vs. 6.6(6.6) ng/dL, respectively, p < 0.001] and a higher estimated 10-year CV risk [7.0(8.6) vs. 1.3(3.6)%, respectively, p < 0.001] compared to controls. The gene discussed is LGALS3; the disease is systemic lupus erythematosus.